Singapore Immunohistochemistry Market Size, Share, and COVID-19 Impact Analysis, By Product (Antibodies, Reagents, Equipment, Kits, and Others), By Application (Diagnostic applications and Research applications), By End Use (Hospitals & Diagnostic Laboratories and Research Institutes), and Singapore Immunohistochemistry Market Insights, Industry Trend, Forecasts to 2035

Singapore Immunohistochemistry Market Insights Forecasts to 2035

• The Singapore Immunohistochemistry Market Size Was Estimated at USD 16.65 Million in 2024
• The Singapore Immunohistochemistry Market Size is Expected to Grow at a CAGR of Around 6.05% from 2025 to 2035
• The Singapore Immunohistochemistry Market Size is Expected to Reach USD 33.27 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Singapore Immunohistochemistry Market size is anticipated to reach USD 33.27 million by 2035, growing at a CAGR of 6.05 from 2025 to 2035. The Singapore immunohistochemistry market is driven by the rising prevalence of cancer and chronic diseases, increasing demand for accurate tissue-based diagnostics, growing adoption of personalized and precision medicine, advancements in automated staining and imaging technologies, and strong healthcare infrastructure and government support for diagnostic innovation.

Market Overview

The Singapore immunohistochemistry market is the industry that encompasses various activities such as research, manufacturing, distribution, and usage of immunohistochemistry reagents, antibodies, instruments, and related services within Singapore. Immunohistochemistry is a method in the laboratory that is used to locate certain antigens in tissue samples, which is extensively utilized in cancer diagnosis, disease classification, biomarker detection, and research. This market caters to the needs of hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies and is fuelled by factors such as increasing disease burden, technological innovations, and a strong encouragement for medical research and diagnostics in Singapore.

Singapore’s adoption of the immunohistochemistry (IHC) market is primarily influenced by the direct population health needs and the rising disease burden. Singapore, with a population of around 5.9 million, has a high and gradually increasing incidence of cancer, which remains one of the leading causes of death in the country. Moreover, the country has an aging population, with about 25 of the residents being 65 years old and above in 2030, which further raises the need for accurate cancer diagnosis, tumor classification, and biomarker testing, in which IHC is essential. The increasing incidences of breast, lung, colorectal, and prostate cancers, together with chronic and autoimmune diseases, signify the necessity for dependable tissue-based diagnostics to facilitate early detection, the selection of targeted therapies, and thus, better patient outcomes.

The market is also strengthened by the strong backing of the government and the availability of research funds. The Singapore government has allocated a total of SGD 25 billion for research and innovation under the RIE 2025 initiative, out of which a big portion is dedicated to health and biomedical sciences, including diagnostics and precision medicine. There is also support in the form of grants from institutions like NMRC and EDB that are paving the way for automated IHC, digital pathology, and biomarker research, thereby making the Singapore immunohistochemistry market highly significant for clinical excellence, personalized healthcare, and long-term investment growth.

Report Coverage

This research report categorizes the market for the Singapore immunohistochemistry market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Singapore immunohistochemistry market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Singapore immunohistochemistry market.

Driving Factors

The Singapore immunohistochemistry (IHC) market is primarily driven by the increasing incidence of cancer, an aging population, and a higher demand for personalized medicine. Moreover, the development of automated and digital IHC technologies, the expansion of healthcare infrastructure, and the government's support via RIE 2025 and research agencies act as additional factors leading to the market growth.

Restraining Factors

The Singapore immunohistochemistry market growth is restrained by the high expense of IHC tests and sophisticated instruments, the lack of skilled manpower, stringent regulatory requirements, and the presence of competing diagnostic methods, such as molecular and genomic testing, that can delay universal adoption.

Market Segmentation

The Singapore immunohistochemistry market share is classified into product, application, and end use.

• The antibodies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Singapore immunohistochemistry market is segmented by product into antibodies, reagents, equipment, kits, and others. Among these, the antibodies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The antibodies segment is growing because antibodies are the core component of immunohistochemistry assays, enabling specific detection of biomarkers and cancer-related antigens in tissue samples. Increasing cancer incidence, demand for precise diagnostics, and adoption of targeted therapies drive strong growth in this segment.

• The diagnostic applications segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The Singapore immunohistochemistry market is segmented by application into diagnostic applications and research applications. Among these, the diagnostic applications segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The diagnostic applications segment is growing because immunohistochemistry is widely used in hospitals and clinical laboratories for accurate cancer diagnosis, tumor classification, and biomarker detection, which are essential for treatment planning, personalized therapies, and improved patient outcomes in Singapore.

• The hospitals & diagnostic laboratories segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Singapore immunohistochemistry market is segmented by end use into hospitals & diagnostic laboratories and research institutes. Among these, the hospitals & diagnostic laboratories segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The hospitals & diagnostic laboratories segment is growing because these facilities are the primary users of immunohistochemistry for clinical diagnostics, handling the majority of cancer testing, biomarker analysis, and patient tissue examinations, which drives strong demand in Singapore.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Singapore immunohistochemistry market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers  acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Thermo Fisher Scientific Inc
• Bio SB
• Bio.etc Pte Ltd
• BioMedix Singapore Pte Ltd
• SciMed Pte Ltd
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

In November 2024, Mirxes and Canhelp Genomics partnered to introduce the PCR based Canhelp Origin tumour identification test in Singapore, enhancing cancer diagnostics by pinpointing solid tumour origins and improving precision treatment strategies.

Market Segment

This study forecasts revenue at the Singapore, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Singapore immunohistochemistry market based on the below-mentioned segments:

Singapore Immunohistochemistry Market, By Produ

• Antibodies
• Reagents
• Equipment
• Kits
• Others

Singapore Immunohistochemistry Market, By Application

• Diagnostic applications
• Research applications

Singapore Immunohistochemistry Market, By End Use

• Hospitals & Diagnostic Laboratories
• Research Institutes